Introduction
============

Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes that arises from one or more mutations in a single gene, and 13 disease genes for MODY have been identified[@b1]; for example, the disease gene of MODY5 is *HNF1B*[@b1]. Each MODY is presumably caused by dysfunction of pancreatic β-cells as a result of mutations in one of those genes. However, pancreatic β-cells of the patients are not easily or ethically available for experiments. Therefore, the molecular mechanisms underlying MODY in humans are largely unknown.

Today, the number of reports describing the generation of disease-specific induced pluripotent stem cells (iPS) cells is increasing[@b2]--[@b4], and, very recently, establishment of Caucasians MODY patient-derived iPS cells has been reported (MODY-iPS cells)[@b5],[@b6]. Because insulin sensitivity and insulin responses differ among Africans, Caucasians and East Asians[@b7], the genetic background should be considered when investigating the pathophysiology of diabetes. Therefore, the establishment of MODY-iPS cell lines from various populations is vital for completely analyzing the pathogenesis of MODY.

In the present research, we established MODY5 (R177X)-iPS cells from a Japanese patient using non-integrating Sendai virus; MODY5 (R177X)-iPS cells had mutations leading to a premature termination codon (PTC). We found for the first time that MODY genes messenger ribonucleic acids (mRNAs) with PTC were degraded by nonsense-mediated mRNA decay (NMD) during differentiation from MODY-iPS cells to pancreatic β-cells.

Material and Methods
====================

Generation of MODY-iPS Cells
----------------------------

Skin fibroblasts were obtained from a MODY5 patient by a 5-mm punch biopsy at Tokyo Women\'s Medical University after written informed consent. We purchased healthy women\'s fibroblasts from Lonza (Verviers, Belgium) as a control. Aliquots of 10^6^ cells of these control and MODY5-patient skin fibroblasts were transduced with *hSOX2*, *hOCT3/4*, *hKLF* and *hC-MYC* using SeV (MBL, Nagano, Japan) overnight. The cells were washed and cultured in Dulbecco\'s modified Eagle medium supplemented 10% fetal bovine serum for 6 days. Then Sev-infected fibroblasts were seeded on mitomycin-treated mouse embryonic fibroblast feeder cells; the next day, the medium was replaced by hiPS medium (Dulbecco\'s modified Eagle medium/F\'12 supplemented with 20% knockout serum replacement, 2 mmol/L [l]{.smallcaps}-glutamine, 0.5× penicillin/streptomycin, 1× non-essential amino acids, 55 μmol/L 2-mercaptoethanol and 7.5 ng/mL FGF2). Then, 3--4 weeks later, primary hiPS colonies appeared, and we transferred each colony onto mitomycin-treated SNL feeder cells. These hiPS colonies were maintained on mitomycin-treated SNL feeder cells and enzymatically passaged using CTK solution at 1:5--1:8 once a week. In the present study, three different control or MODY-iPS cell lines were used, respectively. The experiments were carried out with the approval of the ethical committees in Tokyo Women\'s Medical University and the National Center for Global Health and Medicine.

Detailed Materials and Methods of the items are described in the [Data S1](#SD2){ref-type="supplementary-material"}.

Results
=======

Establishment of MODY5-iPS Cells
--------------------------------

We established MODY-iPS cells using SeV from s Japanese MODY5 patient who had the R177X disease variant, and clinical features were previously characterized[@b8],[@b9]. Although the SeV genome was present in the cytoplasm of the MODY5-iPS colonies at passage 3, we confirmed the complete shedding of the SeV genome by passage 10 by immunocytochemistry (Figure [1](#fig01){ref-type="fig"}m) or reverse transcription polymerase chain reaction (RT--PCR; data not shown), indicating that these cells were transgene-free. We used MODY5-iPS cells more than 10 passages for experiments. The MODY5-iPS cells expressed pluripotency markers, such as OCT3/4, NANOG, SSEA4, TRA-1-60 and TRA-1-81, and had alkaline phosphatase activity (Figures [1](#fig01){ref-type="fig"}b--l and [S1](#SD1){ref-type="supplementary-material"}b--l). Teratoma derived from MODY5-iPS and control hiPS cells contained three germ layers; ectoderm, mesoderm and endoderm (Figures [1](#fig01){ref-type="fig"}p--r and [S1](#SD1){ref-type="supplementary-material"}m--o). We confirmed that the karyotypes of the control and MODY 5-iPS cells were all normal (Figures [1](#fig01){ref-type="fig"}o and [S1](#SD1){ref-type="supplementary-material"}p).

![Characterization of pluripotency of maturity-onset diabetes of the young 5-induced pluripotent stem (MODY5-iPS) cells. (a) Morphology of MODY5-iPS cells. (b) Alkaline phosphatase staining. (c--n) Immunocytochemistry for pluripotency markers. (c) OCT3/4; (e) NANOG; (g) SSEA4; (i) TRA-1-60; (k) TRA-1-81; (d, f, h, j, l) DAPI; (m) SeV, passage 3 (n) SeV, passage 10; (o) karyotype analysis by the G-band method; (p--r) teratoma derived from MODY1-iPS cells; (p) ectoderm -- neural tissue; (q) mesoderm -- muscle and cartilage; and (r) endoderm -- gut tube-like structure.](jdi0006-0543-f1){#fig01}

Detection of Disease Gene mRNAs during Differentiation from MODY-iPS Cells into β-Like Cells
--------------------------------------------------------------------------------------------

The disease gene of MODY5 is *HNF1B*. Expression of *HNF1B* was reported at the primitive gut tube stage during pancreatic β-cell development[@b10],[@b11]. To detect *HNF1B* mRNA, control or MODY-iPS cells were differentiated into pancreatic β-cells using five-stage protocols[@b10], and expression of marker genes for each stage was investigated by RT--PCR (Figure [2](#fig02){ref-type="fig"}a,b). We confirmed that *HNF1B* mRNA as well as *Sox17*, *FoxA2* and *HNF4A* mRNA were expressed at the primitive gut tube stage (Figure [2](#fig02){ref-type="fig"}b). Immunocytochemistry showed that both control and MODY5-iPS cells differentiated into the primitive gut tube at the same level, because more than 90% of the cells were positive for HNF1B and Sox17 (Figure [2](#fig02){ref-type="fig"}c).

![Differentiation of pancreatic β-cells from maturity-onset diabetes of the young 5-induced pluripotent stem (MODY5-iPS) cells. (a) Scheme of the differentiation process and cloning of disease genes. Definitive endoderm (DE), primitive gut tube (PGT), posterior foregut (PFG) and endocrine progenitor (EP). (b) Expression of marker genes for each stage by reverse transcription polymerase chain reactions (RT--PCR). Undifferentiation (undiff). *OAZ1* is a housekeeping gene used as a loading control. (c) Immunocytochemistry of control or MODY5-IPS cells at PGT. (a\'--d') control iPS cells. (e'--h') MODY5-iPS cells. (a', e') HNF1B: green, (b', d', f', h') DAPI: blue, (c', g') SOX17: red.](jdi0006-0543-f2){#fig02}

R177X Mutant mRNA Are Destroyed in Differentiated MODY-iPS Cells and Restored by Treatment with Cycloheximide
-------------------------------------------------------------------------------------------------------------

The mutation site of our MODY5 patient was exon 2 of *HNF1B* and caused PTC (Figure [3](#fig03){ref-type="fig"}a), which is regarded as a tag of mRNA degradation by NMD[@b12],[@b13]. Therefore, we amplified disease gene mRNA by RT--PCR and sequenced them. We confirmed that two bold signals with almost the same strength (C, wild and T, mutant) were present at the mutation site of the genomic sequence of the MODY5-iPS cell (Figure [3](#fig03){ref-type="fig"}b). In contrast to the genomic sequence, one definite signal (C) derived from wild mRNA existed at the mutation site, whereas the signal (T) of R177X mutant mRNA was very weak (Figure [3](#fig03){ref-type="fig"}c), showing that the R177X mutant mRNA might be decayed by the NMD pathway. To confirm this, differentiated MODY-iPS cells were treated with cycloheximide to inhibit NMD. Cycloheximide treatment clearly enhanced the sequence signal of R177X mutant mRNAs compared with non-treated samples (Figure [3](#fig03){ref-type="fig"}c,d). We also confirmed that the sequence of *HNF1b* mRNA derived from control iPS cells had only clear wild-type transcript signals (Figure [3](#fig03){ref-type="fig"}e).

![Detection of R177X mutation in genomic deoxyribonucleic acid and messenger ribonucleic acid (mRNA). (a) Genomic structure of *HNF1B* in the maturity-onset diabetes of the young 5 (MODY5) patient. The original start and stop codons existed in exons 1 and 9, respectively. In the case of the R177X mutation, a nonsense mutation was present at exon 2 (C is replaced by T) leading to a premature termination codon (PTC). (b--e) Sequence data for the *HNF1B* gene and transcripts of control or MODY5-induced pluripotent stem (iPS) cells at the primitive gut tube stage. (b) Genomic sequence data for the MODY5-iPS cells near the mutation site. (c) Sequence data cloned from transcripts derived from MODY5-iPS cells, (d) cycloheximide (CHX)-treated MODY5-iPS cells and (e) control iPS cells.](jdi0006-0543-f3){#fig03}

Discussion
==========

Recently, Caucasian MODY-iPS cells were established by two groups[@b5],[@b6]. However, MODY-iPS cells from Asian patients have never been reported. In the present research, we reported the establishment of MODY-iPS cells from a Japanese MODY5 patient who had the R177X mutation. Among MODY-iPS cells previously established, only MODY2-iPS cells have been used to examine the function of disease gene encoding glycolytic enzyme glucokinase at β-like cells[@b6]. We examined the disease gene mRNA encoding transcription factor *HNF1B*, and confirmed disruption of R177X mutant mRNA with PTC during the developmental process of pancreatic β-cells from MODY-iPS cells for the first time. Although destruction of several MODY3 and MODY5 (not including R177X) mutant mRNAs with PTC was previously reported using ectopic transcripts artificially made from Epstein--Barr virus-transformed lymphoblastoid cells or tubule cells[@b14],[@b15], our results clearly showed that a mutant transcript with PTC is rapidly destroyed by NMD during the developmental stages of pancreatic β-cells, before the onset of MODY.

Thus, MODY-iPS cell technologies make it possible to obtain actual cells expressing MODY genes by differentiating MODY-iPS cells to pancreatic β-cells. Further study will be required for understanding the pathogenesis.
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**Figure S1 \|** Characterization of pluripotency of control cells.
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**Data S1 \|** Supporting materials and methods.
